🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our #ASH23 poster on meta-analysis of myeloid sarcoma, #3811, in 900s section. One of the largest cohorts of myeloid sarcoma, pooled to gain insights on the disease! Cc: Dakshin Padmanabhan #ASHKudos to mentor and PI Suresh Balasubramanian ash.confex.com/ash/2023/webpr…

Grateful to share this study with Yi Lee, MD, a step in understanding the quality of life of breast cancer patients. Most thankful for our mentor's dedication (Dr Judie Goodman) to breast cancer patients and for imparting that passion to us. SABCS

Grateful to be a part of this work on myeloid sarcoma! Suresh Balasubramanian Jeff Aguilar

.UCSD Health Moores Cancer Center COE researchers led by Dr. Nathan Jayne found that truncation of RUNX1 results in the dysregulation of #hematopoietic and oncogenic pathways through changes in enhancer-promoter networks. 🖨️ Blood Advances 📰 bit.ly/3R048Ae

Grateful to present work on domain-based analysis of somatic RUNX1 mutations in myeloid neoplasms at #ASCO24 Meeting! Cc Jeff Aguilar Many thanks to mentor Suresh Balasubramanian

How do TP53 configurations evolve with treatment and impact prognosis? Dakshin Padmanabhan will present intriguing findings tonight. Don’t miss it! #ASH24 ASH Wayne State University Karmanos Cancer Institute Karmanos Hematology/Oncology Fellowship Vik Dhillon Jeff Aguilar

Grateful to present work on TP53 mutated myeloid neoplasms at the ASH 2024 meeting! Excited to soon join Karmanos Hematology/Oncology Fellowship next summer! Cc Jeff Aguilar Many thanks to my mentor Suresh Balasubramanian

➡️ Check out our paper on Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms Haematologica haematologica.org/haematologica/… ✅ A clinically relevant and easy to use TP53 aberration burden stratification and a closer look at outcomes

🩺 2022 ELN AML Risk Stratification🌟 📊 Cytogenetic & molecular updates for AML prognostics: ✅ Favorable: RUNX1::RUNX1T1, CBF::MYH11, Mutated NPM1 🧬 ⚖️ Intermediate: FLT3-ITD, MLLT3::KMT2A ❌ Adverse: TP53 🧬, MECOM, Complex/Monosomal Karyotype 🔗 Stay updated #AML #Hematology

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007 onclive.com/view/ziftomeni… via @onclive

MDS with a single TP53 mutation and CK is similar to MDS with biallelic TP53 abnormalities, whereas TP53-mutated AML is distinct from AML-MR. ow.ly/Jjpn50UYybi #myeloidneoplasia

check out this new paper featuring Caner Saygin, MD as co-author which looks at the impact of TP53 mutations and TET2 deficiency on leukemogenesis! pubmed.ncbi.nlm.nih.gov/40111422/

About 50% of patients developing systolic dysfunction during AML induction fail to recover LVEF 😳 Older males with pre-existing 🫀 comorbidities were most likely to NOT recover LVEF 🤷🏽‍♂️ #MedTwitter ascopubs.org/doi/10.1200/OP…

The term “unexplained cytopenia” is used to describe a condition characterized by peripheral blood cytopenia that cannot be attributed to identifiable causes using conventional tests or to any concomitant diseases. ow.ly/1AES50VyEKw #HowITreat #myeloidneoplasia

FLT3-ITD MRD can identify which patients benefit from gilteritinib maintenance. ow.ly/B79T50VPLu4 #clinicaltrialsandobservations #myeloidneoplasia